BMY

Bristol‑Myers Squibb (BMY) is a global biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, primarily in oncology, immunology, hematology, cardiovascular disease and related therapeutic areas. Its business model relies on high‑science research and a robust pipeline of biologics, small‑molecule drugs and cell‑therapy products, with major brands such as Opdivo (nivolumab), Eliquis (apixaban) and Revlimid (lenalidomide) generating ongoing revenue. The firm operates in the healthcare/pharmaceutical sector and is considered one of the leading innovators in cancer immunotherapy and cardiovascular therapeutics, maintaining a strong presence across the United States, Europe, Asia and emerging markets. BMS’s scale, extensive R&D investment and strategic collaborations position it among the top tier of multinational pharmaceutical companies.